<PAGE>
FORM 8-A
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Pharmaceutical HOLDRs/SM/ Trust
(Exact name of registrant as specified in its charter)
New York not applicable
(State of incorporation or organization) (I.R.S. Employer
Identification No.)
c/o The Bank of New York, as Trustee
101 Barclay Street, 22-W
New York, New York 10286
(Address of principal executive offices) (Zip Code)
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange on which
to be so registered: each class is to be registered:
Pharmaceutical HOLDRs American Stock Exchange
If this form relates to the registration of a class of securities pursuant
to Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c), check the following box. [x]
If this form relates to the registration of a class of securities pursuant
to Section 12(g) of the Exchange Act and is effective pursuant to General
Instruction A.(d), check the following box. [ ]
Securities Act registration file number to which this form relates:
333-92161
333-95805
Securities to be registered pursuant to Section 12(g) of the Act:
None
<PAGE>
2
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. Description of Registrant's Securities to be Registered.
The description of the 1,000,000,000 Depositary Receipts to be issued by
the Pharmaceutical HOLDRs Trust (the "Pharmaceutical HOLDRs") to be registered
hereunder is set forth under the caption entitled "Description of Pharmaceutical
HOLDRs" in the prospectus (the "Prospectus") that forms part of the registrant's
registration statement on Form S-1 (Registration No. 333-95805) filed with the
Securities and Exchange Commission under the Securities Act of 1933, as amended
(the "Securities Act") on January 31, 2000. Pursuant to Rule 429 of the
Securities Act the Pharmaceutical HOLDRs registered pursuant to the registrant's
registration statement on Form S-1 (Registration No 333-92161) filed with the
Securities and Exchange Commission under the Securities Act on December 6, 1999,
as amended by Amendment No. 1 thereto, filed on December 21, 1999 are covered by
such Prospectus. The description of the Pharmaceutical HOLDRs contained in the
Prospectus and both of the registration statements are hereby incorporated by
reference. Definitive copies of the Prospectus describing the Pharmaceutical
HOLDRs will be filed with the Securities and Exchange Commission pursuant to
Rule 424(b) of the Securities Act, and shall be incorporated by reference into
this Registration Statement on Form 8-A.
Item 2. Exhibits.
1. Form of Depositary Trust Agreement is set forth in Exhibit 4.1 to
the Registration Statement and is incorporated herein by
reference.
2. Form of Pharmaceutical HOLDRs is set forth in Exhibit 4.1 to the
Registration Statement and is incorporated herein by reference.
<PAGE>
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange
Act of 1934, the registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereto duly authorized.
MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED, as Initial Depositor,
on behalf of
Pharmaceutical HOLDRS Trust
Date: January 31, 2000 By:/S/ STEPHEN G. BODURTHA
---------------------------------
Name: Stephen G. Bodurtha
Title: Attorney-in-Fact
